식품의약품안전청에 보고된 심혈관계 약물유해반응의 특성 분석
Characteristics of Cardiovascular Adverse Drug Reactions Reported to KFDA
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Adverse drug reaction (ADR) is a global problem of major concern in health care. ADRs can be accrued in any organs or systems. However, cardiovascular ADRs could be a more serious problem if they are irreversible or severe. For this reason, this study was conducted to analyze pattern and severity of cardiovascular ADRs, and suspicious medication. Total 646 reports including cardiovascular ADRs reported to the KFDA between January and June 2010 were analyzed. Amlodipine besylate (36 reports, 3.3%), iopromide (29 reports, 2.7%), tramadol HCl (28 reports, 2.6%) were most suspicious drugs that occurred cardiovascular ADRs. The most common cardiovascular ADRs were hypotension(236 reports, 33.1%), palpitation (134 reports, 18.8%), and hypertension (89 reports, 12.5%). The most frequent ADRs were occurred in the age group of more than 60. This result could be of help to prescribers and other healthcare providers to predict and prevent cardiovascular ADRs. Also this study suggested that patients with cardiovascular ADR risk factors should be intensively monitored during the medications
Abstract
Adverse drug reaction (ADR) is a global problem of major concern in health care. ADRs can be accrued in any organs or systems. However, cardiovascular ADRs could be a more serious problem if they are irreversible or severe. For this reason, this study was conducted to analyze pattern and severity of cardiovascular ADRs, and suspicious medication. Total 646 reports including cardiovascular ADRs reported to the KFDA between January and June 2010 were analyzed. Amlodipine besylate (36 reports, 3.3%), iopromide (29 reports, 2.7%), tramadol HCl (28 reports, 2.6%) were most suspicious drugs that occurred cardiovascular ADRs. The most common cardiovascular ADRs were hypotension(236 reports, 33.1%), palpitation (134 reports, 18.8%), and hypertension (89 reports, 12.5%). The most frequent ADRs were occurred in the age group of more than 60. This result could be of help to prescribers and other healthcare providers to predict and prevent cardiovascular ADRs. Also this study suggested that patients with cardiovascular ADR risk factors should be intensively monitored during the medications
참고문헌 (27)
- Bates DW, "Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention", JAMA, 274(1), pp.29~34 (1994)
- Lazarou J, "Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies", JAMA, 279(15), pp.1200~1205 (1998)
- Hallas J, "Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention", J Intern Med, 228(2), pp.83~90 (1990)
- Lundkvist J, "Pharmacoeconomics of adverse drug reactions", Fundam Clin Pharmacol, 18(3), pp.275~280 (2004)
- Pirmohamed M, "Cytochrome P450 enzyme polymorphisms and adverse drug reactions", Toxicology, 192(1), pp.23~32 (2003)
- Bates DW, "The cost of adverse drug event in hospitalized patients. Adverse drug events prevention study group", JAMA, 277(4), pp.307~311 (1997)
- 송명균, "약물유해반응의 인과관계 판정을 위한 Naranjo와 WHO-UMC 지표의 비교", 대한내과학회지, 74(2), pp.181~187 (2008), 대한내과학회
- 김민강, "단일기관에서 전산을 통해 수집된 자발적 약물유해반응 보고사례들의 분석", 대한내과학회지, 77(5), pp.601~609 (2009), 대한내과학회
- 이진이, "의약품 부작용의 심각도 조사 비교분석", 한국임상약학회지, 21(3), pp.237~242 (2011), 한국임상약학회
- Fitzgerald GA, "Coxibs and cardiovascular disease", N Engl J Med, 351(17), pp.1709~1711 (2004)
- Schmidt H, "Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis", Drug Saf, 27(3), pp.185~196 (2004)
- Kaul S, "Diabetes: Breaking news! Rosiglitazone and cardiovascular risk", Nat Rev Cardiol, 7(12), pp.670~672 (2010)
- Yee MS, "The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk", Diabet Med, 27(12), pp.1392~1400 (2010)
- Scheen AJ, "Cardiovascular risk-benefit profile of sibutramine", Am J Cardiovasc Drugs, 10(5), pp.321~324 (2010)
- Broeyer FJ, "Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy", J Cancer Res Clin Oncol, 134(9), pp.961~968 (2008)
- Smith LA, "Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials", BMC Cancer, 10, pp.337~350 (2010)
- 신현택, "의약품 부작용에 관한 국제 분류체계인 WHO-ART와 MedDRA의 비교분석", 한국임상약학회지, 17(1), pp.46~52 (2007), 한국임상약학회
- Hartwig SC, "Preventability and severity assessment in reporting adverse drug reactions", Am J Hosp Pharm, 49(9), pp.2229~2232 (1992)
- Tharpe N, "Adverse drug reactions in women's health care", J Midwifery Womens Health, 56(3), pp.205~213 (2011)
- Hofer-Dueckelmann C, "Adverse drug reactions (ADRs) associated with hospital admissions - elderly female patients are at highest risk", Int J Clin Pharmacol Ther, 49(10), pp.577~586 (2011)
- 김현아, "약물유해반응 보고에 대한 개국약국 약사들의 태도 및 지식에 관한 연구", 한국임상약학회지, 19(2), pp.159~166 (2009), 한국임상약학회
- Francisca G, "Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study", Pharmacoepidemiol Drug Saf, 20(12), pp.1287~1294 (2011)
- 김정은, "노인 입원환자에서 발생한 약물유해반응의 특성", 천식 및 알레르기, 30(3), pp.216~221 (2010), 대한천식알레르기학회
- 최남경, "자발적 부작용신고제도 인식도 및 약물 유해사례 경험에 대한 설문조사: 고양시 의사 및 약사를 대상으로", 약물역학위해관리학회지, 1(1), pp.44~52 (2008)
- 송홍지, "약물부작용 감시와 가정의의 역할", Korean Journal of Family Medicine, 28(11), pp.815~823 (2007), 대한가정의학회